AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
AstraZeneca's total debt was $29.49B at Jun 30, 2026. For fiscal 2025 it was $27.82B, down 3.6% from the year before. Over ten years it grew 6.3% a year on average. The highest annual figure on record is $29.79B in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.82B | -3.6% |
| FY2024 | Dec 31, 2024 | $28.84B | +4.9% |
| FY2023 | Dec 31, 2023 | $27.49B | -2.8% |
| FY2022 | Dec 31, 2022 | $28.28B | -5.1% |
| FY2021 | Dec 31, 2021 | $29.79B | +51.2% |
| FY2020 | Dec 31, 2020 | $19.70B | +12.2% |
| FY2019 | Dec 31, 2019 | $17.55B | -8.2% |
| FY2018 | Dec 31, 2018 | $19.11B | +7.3% |
| FY2017 | Dec 31, 2017 | $17.81B | +5.9% |
| FY2016 | Dec 31, 2016 | $16.81B | +11.7% |
| FY2015 | Dec 31, 2015 | $15.05B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.49B | -8.7% |
| Q4 FY2025 | Dec 31, 2025 | $27.82B | +1.2% |
| Q2 FY2025 | Jun 30, 2025 | $31.21B | +8.0% |
| Q4 FY2024 | Dec 31, 2024 | $28.84B | +2.0% |
| Q2 FY2024 | Jun 30, 2024 | $32.29B | +12.8% |
| Q4 FY2023 | Dec 31, 2023 | $27.49B | -7.7% |
| Q2 FY2023 | Jun 30, 2023 | $28.89B | +7.8% |
| Q4 FY2022 | Dec 31, 2022 | $28.28B | +43.6% |
| Q2 FY2022 | Jun 30, 2022 | $28.62B | +49.8% |
| Q4 FY2021 | Dec 31, 2021 | $29.79B | +69.7% |
| Q2 FY2021 | Jun 30, 2021 | $26.81B | +41.2% |
| Q4 FY2020 | Dec 31, 2020 | $19.70B | +3.1% |
| Q2 FY2020 | Jun 30, 2020 | $19.11B | -2.8% |
| Q4 FY2019 | Dec 31, 2019 | $17.55B | -1.4% |
| Q2 FY2019 | Jun 30, 2019 | $18.98B | -3.8% |
| Q4 FY2018 | Dec 31, 2018 | $19.11B | +13.7% |
| Q2 FY2018 | Jun 30, 2018 | $19.67B | +30.7% |
| Q4 FY2017 | Dec 31, 2017 | $17.81B | – |
| Q2 FY2017 | Jun 30, 2017 | $19.73B | – |
| Q4 FY2016 | Dec 31, 2016 | $16.81B | – |
| Q4 FY2015 | Dec 31, 2015 | $15.05B | – |
See a number that looks wrong?